FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

NASDAQ:FENC • CA31447P1009

8.97 USD
+0.29 (+3.34%)
At close: Feb 18, 2026
8.97 USD
0 (0%)
After Hours: 2/18/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, FENC scores 2 out of 10 in our fundamental rating. FENC was compared to 521 industry peers in the Biotechnology industry. FENC may be in some trouble as it scores bad on both profitability and health. FENC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year FENC has reported negative net income.
  • In the past year FENC has reported a negative cash flow from operations.
  • In the past 5 years FENC always reported negative net income.
  • In the past 5 years FENC reported 4 times negative operating cash flow.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

  • The Return On Assets of FENC (-14.09%) is better than 80.42% of its industry peers.
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

  • FENC has a better Gross Margin (93.12%) than 93.86% of its industry peers.
  • FENC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The number of shares outstanding for FENC has been increased compared to 1 year ago.
  • The number of shares outstanding for FENC has been increased compared to 5 years ago.
  • The debt/assets ratio for FENC has been reduced compared to a year ago.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -1.72, we must say that FENC is in the distress zone and has some risk of bankruptcy.
  • FENC has a Altman-Z score (-1.72) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • FENC has a Current Ratio of 4.69. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
  • FENC has a Current ratio (4.69) which is in line with its industry peers.
  • A Quick Ratio of 4.44 indicates that FENC has no problem at all paying its short term obligations.
  • FENC has a Quick ratio (4.44) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.44
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • FENC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -475.00%.
  • FENC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.39%.
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%

3.2 Future

  • Based on estimates for the next years, FENC will show a very strong growth in Earnings Per Share. The EPS will grow by 211981.00% on average per year.
  • The Revenue is expected to grow by 26.94% on average over the next years. This is a very strong growth
EPS Next Y-248058267475566850%
EPS Next 2Y10558111022.08%
EPS Next 3Y26458100%
EPS Next 5Y211981%
Revenue Next Year-20.03%
Revenue Next 2Y16.86%
Revenue Next 3Y19.53%
Revenue Next 5Y26.94%

3.3 Evolution

FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FENC. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 14.50, the valuation of FENC can be described as correct.
  • Based on the Price/Forward Earnings ratio, FENC is valued cheaply inside the industry as 96.35% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of FENC to the average of the S&P500 Index (28.16), we can say FENC is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 14.5
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • FENC's earnings are expected to grow with 26458100.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10558111022.08%
EPS Next 3Y26458100%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for FENC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (2/18/2026, 8:00:00 PM)

After market: 8.97 0 (0%)

8.97

+0.29 (+3.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-09
Inst Owners42.53%
Inst Owner Change0.66%
Ins Owners1.85%
Ins Owner Change0.93%
Market Cap306.33M
Revenue(TTM)38.79M
Net Income(TTM)-6.94M
Analysts85
Price Target15.5 (72.8%)
Short Float %2.72%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.59%
Min EPS beat(2)-199.56%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-67.7%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-157.9%
EPS beat(12)5
Avg EPS beat(12)-104.64%
EPS beat(16)6
Avg EPS beat(16)-92.56%
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)-10.17%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)8.54%
Revenue beat(8)4
Avg Revenue beat(8)-7.28%
Revenue beat(12)6
Avg Revenue beat(12)2.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.83%
PT rev (3m)10.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-65.14%
EPS NY rev (1m)-8.87%
EPS NY rev (3m)-86.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.5
P/S 7.9
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)0.62
Fwd EY6.9%
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.14
BVpS-0.13
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.12%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.44
Altman-Z -1.72
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y-248058267475566850%
EPS Next 2Y10558111022.08%
EPS Next 3Y26458100%
EPS Next 5Y211981%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
Revenue Next Year-20.03%
Revenue Next 2Y16.86%
Revenue Next 3Y19.53%
Revenue Next 5Y26.94%
EBIT growth 1Y-340.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year269.89%
EBIT Next 3Y327.46%
EBIT Next 5YN/A
FCF growth 1Y60.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FENC FAQ

What is the fundamental rating for FENC stock?

ChartMill assigns a fundamental rating of 2 / 10 to FENC.


Can you provide the valuation status for FENNEC PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 2 / 10 to FENNEC PHARMACEUTICALS INC (FENC). This can be considered as Overvalued.


What is the profitability of FENC stock?

FENNEC PHARMACEUTICALS INC (FENC) has a profitability rating of 2 / 10.


What is the financial health of FENNEC PHARMACEUTICALS INC (FENC) stock?

The financial health rating of FENNEC PHARMACEUTICALS INC (FENC) is 3 / 10.


What is the earnings growth outlook for FENNEC PHARMACEUTICALS INC?

The Earnings per Share (EPS) of FENNEC PHARMACEUTICALS INC (FENC) is expected to decline by -248058267475566850% in the next year.